, ARB vs. CCB) and speci c agent should be based on local availability and cost. Rationale This recommendation places a higher value on preventing kidney allograft loss and a lower value on the risk of medication-related side effects. There are many advantages of using an ARB or CCB for high BP in kidney transplant recipients, including physician familiarity with these agents, well-known side-effect pro les, availability, and low costs. This recommendation is strong because, in the judgment of the Work Group, the potential prevention of transplant www.kidney-international.org chapter 4 failure far outweighs potential risks and burden associated with its implementation. The Work Group also judged that most transplant patients would take a CCB or an ARB given the potential bene t, and only a small proportion would not. Finally, the Work Group judged that the majority, if not all, of clinicians would be comfortable in starting a CCB or ARB due to the familiarity with these agents and their well-known safety pro les. Research recommendations Future research should include:  Adequately powered RCT to evaluate CV and kidney effects of targeting SBP <120 mm Hg versus <130 mm Hg SBP among patients with kidney transplants.  Adequately powered RCT to evaluate CV and kidney effects of ARB versus dihydropyridine CCB among patients with kidney transplants. chapter 4 www.kidney-international.org Chapter 5: Blood pressure management in children with CKD Recommendation 5.1: We suggest that in children with CKD, 24-hour mean arterial pressure (MAP) by ABPM should be lowered to 50th percentile for age, sex, and height (2C). This recommendation is weak, according to GRADE, because the potential risks for adverse events from BP lowering may vary depending on the underlying cause of CKD in children. 